Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term....

Seeking Alpha - 5/12/2025 12:35:14 PM More News for REGN
Stock Analysis for REGN
Related Stocks: